Professional Documents
Culture Documents
PK7400 Automated Microplate System: Legally Marketed Device Manufacturer 510 (K) Number Clearance Date
PK7400 Automated Microplate System: Legally Marketed Device Manufacturer 510 (K) Number Clearance Date
1.0 Submitted By
Raya D. Zerger
Senior Staff, Regulatory Affairs
Beckman Coulter, Inc.
250 S. Kraemer Blvd.
Brea, CA 92821 USA
Telephone: 305.380.2624
Fax: 714.961.4234
Page 5-1
510(k) Summary
PK7400 Automated Microplate System
.
that are cleared or approved and are labeled indicating their use on this system for
blood donor screening. This system is for in vitro diagnostic use only.
The PK7400 is the successor to the PK7300 Automated Microplate System. These
devices have same / similar design and modes of operation. An overview of the
functional similarities and differences are summarized in Table 6.0.
Page 5-2
510(k) Summary
PK7400 Automated Microplate System
.
Page 5-3
510(k) Summary
PK7400 Automated Microplate System
.
Clinical Studies
Results from the PK7400 and reagents intended for use with the PK7400 for
blood donor testing were compared to results from the PK7300 and associated
on-market reagents for blood donor testing in three geographically diverse clinical
study sites. In addition, testing was conducted by each of the study sites, using
the same panel of samples, to demonstrate reproducibility and/or repeatability
under the testing conditions described by the Instructions for Use for each
reagent.
Non-Clinical Studies
Non-clinical studies were conducted in-house by the reagent manufacturers
to verify performance of the reagents on the PK7400. Data from these studies
was used to demonstrate the ability of the PK7400 together with the reagents to
detect weakly reactive samples or those with weak or variant antigen
expressions.
Conclusion:
The PK7400 Automated Microplate System is substantially equivalent to the PK7300
Automated Microplate System. The devices have same / similar design and modes
of operation. The similarities and differences are summarized in table (Table 6.0).
Substantial equivalence has been demonstrated through performance of donor
ABO/Rh, Rh and Kell phenotyping with Diagast reagents. Performance testing
conducted verifies that the device functions as intended and that design
specifications have been satisfied.
This 510(k) summary is being submitted in accordance with the requirements of the
Safe Medical Device Act of 1990 and the implementing regulation 21 CFR 807.92.
Page 5-4